Serina Therapeutics reports Q2 net income $5.2M but warns of going concern doubt

Serina Therapeutics, Inc.

2024-Q2 EPS reported -$1.74 revenue$56,000

Net income $5.2M ($0.61 basic EPS) includes $9.3M non-cash warrant revaluation; operating loss $3.8M.
Cash and restricted cash $6.1M at June 30; $11.2M owed to Juvenescence; substantial doubt about continuing as going concern.
Research and development expenses $1.6M (+$1.1M YoY); G&A $2.3M (+$1.8M YoY) partly from Merger costs.
Partnered with Enable Injections to develop SER-252 (POZ-apomorphine) for Parkinson's; IND planned for 2025.
Appointed Dr. Srini Tenjarla as SVP of CMC & Formulation; presented POZ-lipid immunogenicity data.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.